[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555471":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":47,"collaborators":50,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":19,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":19,"enrollmentInfo":95,"targetDuration":19,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":19,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention arm","EXPERIMENTAL","second haploidentical stem cell transplantation",[13],"Other: second allogeneic stem cell transplantation",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"second allogeneic stem cell transplantation","1. Change another donor if possible\n2. Conditioning regimen: fludarabine (30mg\u002Fm2\u002Fday, days -6 to -2 ), cyclophosphamide (1g\u002Fm2\u002Fday, days -5 to -4)\n3. GVHD prophylaxis: cyclosporine A (concentration 150-250ng\u002Fml), mycophenolate mofetil (0.5g bid -3d to neutrophil engraftment)+anti CD25 monoAb (20mg -1d, +4d, +15d)",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Xiao-Jun Huang, M.D.","Institute of Hematology, Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Yu-qian Sun, M.D.","CONTACT","+86-10-88324577","sunyuqian83@hotmail.com",[32],{"facility":5,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"RECRUITING","Beijing","Beijing Municipality","100044","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},[46],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},{"type":24,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Xiao-Jun Huang","Prof.",[51,53,55,57,59,62,64,66,68,70,72,74,76,78,80,82,84],{"name":52,"class":6},"The First Affiliated Hospital of Soochow University",{"name":54,"class":6},"Ruijin Hospital",{"name":56,"class":6},"Zhejiang University",{"name":58,"class":6},"First Affiliated Hospital of Xinjiang Medical University",{"name":60,"class":61},"Shandong Provincial Hospital","OTHER_GOV",{"name":63,"class":6},"Guangdong Provincial Hospital of Traditional Chinese Medicine",{"name":65,"class":6},"First Affiliated Hospital of Fujian Medical University",{"name":67,"class":6},"Hebei Yanda Ludaopei Hospital",{"name":69,"class":6},"Tongji Hospital",{"name":71,"class":6},"The First Affiliated Hospital of Zhengzhou University",{"name":73,"class":6},"Peking University First Hospital",{"name":75,"class":6},"Jiangsu Provincial People's Hospital",{"name":77,"class":6},"Shengjing Hospital",{"name":79,"class":6},"Xinqiao Hospital of Chongqing",{"name":81,"class":6},"Nanfang Hospital, Southern Medical University",{"name":83,"class":6},"First Affiliated Hospital of Guangxi Medical University",{"name":85,"class":61},"Anhui Provincial Hospital","100555471","second-haplo-transplantation-for-graft-failure-100555471",false,"NCT06512519","Second Haplo-transplantation for Graft Failure","A Multicenter Prospective Study of Second Haploidentical Transplantation for Graft Failure After the First Haploidentical Transplantation","Inclusion Criteria:\n\n* 1\\. Primary disease: hematological malignancies (AML, CML, MDS, lymphoma, etc.); 2. Graft failure after the first haploidentical stem cell transplantation; 3. Time from the first transplantation to the second transplantation is less than 180 days; 4. Age≥14 years.\n\nExclusion Criteria:\n\n* 1\\. Active infections; 2. Active GVHD; 3. Organ dysfunction: hepatic injury (Tbil≥2ULN), renal injury (Cr≥1.5ULN), heart injury (EF%\\\u003C50% or symptomatic heart failure); 4. Eastern Cooperative Oncology Group (ECOG) score\\>2; 5. Expected life time\\\u003C30 days; 5. Patients could not cooperate; 6. Other situations that are considered inappropriate for enrollment by the investigators,","ALL","14 Years",{"count":96,"type":97},34,"ESTIMATED","INTERVENTIONAL",[100],"NA","Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage. There are no recommended regimens for second transplantations for graft failure, especially in the haploidentical transplant setting. We recently reported encouraging outcomes using a novel method (haploidentical transplantation from a different donor after conditioning with fludarabine and cyclophosphamide). However, the study was performed in single-center and with very small sample size. Therefore, it should be further validated via multicenter study. In this multi-center study, we aim to further evaluate the safety and efficacy of this protocol.",[103,104],"Graft Failure","Stem Cell Transplant Complications","2024-11-05",{"date":107,"type":108},"2024-11-07","ACTUAL",{"date":110,"type":108},"2024-07-01",{"date":112,"type":97},"2027-06",{"name":5,"class":6},1]